PRESS RELEASE **FOR IMMEDIATE PUBLICATION**

Proge Farm® granted to Lallemand Health Solutions the additional European license for oral *L. plantarum* PROGE P17630® Following After-Sales Success

Lallemand Health Solutions and Proge Farm® are proud to announce a new milestone in their partnership: after remarkable after-sales success across the extra-EU market, the two companies have signed a new agreement on L. plantarum PROGE P17630® for oral use.

This agreement covers all European territories, reinforcing the two Companies' position as leading providers of scientifically supported probiotics for women's health. The strain, originally licensed from Proge Farm® to Lallemand for Asia, the Americas, France, and the Czech Republic under the first agreement signed on June 30, 2020, is now available as *Lactiplantibacillus plantarum* P17630 in Europe, also inside Lallemand's blends.

Mirabel, Canada, December 7, 2025 – "This achievement reflects the strong market adoption and trust in *Lactiplantibacillus plantarum* PROGE P17630® as a natural solution for women's intimate health. Expanding our licensing rights worldwide allows us to deliver this unique strain to more women seeking effective, convenient oral probiotics" said Isabelle Champié, Vice President Sales and Marketing at Lallemand Health Solutions.

Novara, Italy, December 7, 2025 – "We are proud to strengthen our collaboration with Lallemand Health Solutions, a global leader in probiotics. Following the registration in Europe of our Live Biotherapeutic Product for vaginal use based on our *Lactiplantibacillus plantarum* P17630, this agreement reinforces the possibility for our strain to reach women everywhere also for oral administration, improving quality of life through science-backed solutions" added Giancarla Dondi, CEO of Proge Farm®.

Global Leadership in Women's Health Probiotics

With this new agreement, Proge Farm® and Lallemand Health Solutions strengthen their leadership in the women's health probiotics segment, a fast-growing niche driven by consumer demand for natural, effective solutions for intimate health. Proge Farm® and Lallemand share the same approach, combining scientific rigor, regulatory expertise, and global reach to deliver premium probiotic solutions that improve women's quality of life.

Marketing and Health Canada Recognition

Lactiplantibacillus plantarum PROGE P17630® (Rosella®), offers women a convenient oral solution for intimate health. In September 2021, Health Canada officially recognized the strain's benefits, granting claims such as:

- Helps support female or vaginal health
- Maintains a healthy vaginal microbiome

This recognition confirms the strain's strong scientific foundation and global credibility, reinforcing its role as a trusted solution for women's health.

About *Lactiplantibacillus plantarum* PROGE P17630® for oral use

- Isolated from healthy vaginal flora
- Supported by **six clinical studies** involving over **800 women**, including oral administration
- Demonstrated benefits for maintaining vaginal balance and supporting conventional treatments for recurrent vulvovaginal candidiasis (rVVC)
- Convenient oral dosage: **5B CFU/day**

About Proge Farm®: From laboratory to market

Founded in Italy in 1992, Proge Farm® develops, produces, registers and puts on the markets, either directly or through licensees, its documented products based on selected probiotic strains for specific therapeutic areas: gastrointestinal, dermatological and gynecological environment. Those products are classified as Live Biotherapeutic Products and food supplements, marketed by Proge Farm®'s sales force directly or by reliable licensees. The constant commitment to research and innovation is one of Proge Farm®'s strengths, confirmed by scientific collaborations with leading universities and by the international certifications of its research laboratory, the site of production and the company's quality system. Since 2010, Proge Farm® produces its bacterial strains in its GMP manufacturing plant.
Since 2021 Proge Farm® has been recognized as Innovative SME.

About Lallemand Health Solutions – Leading Probiotics Forward

With over 90 years of expertise, Lallemand Health Solutions is a global leader in the probiotic industry, specializing in the development, production, and marketing of bacteria- and yeast-based probiotic supplements for human health. From lab to shelf, Lallemand Health Solutions offers premium probiotic solutions backed by robust scientific evidence, regulatory expertise, and global manufacturing capabilities. With

over 600 probiotic formulas marketed in more than 70 countries, the company's solutions support gut health, immune function, mental well-being, and more. Lallemand's commitment to scientific excellence is reflected in its ambitious research program and adherence to Good Manufacturing Practices.

Press Contact
Marilou Luneau, Communications Manager
Lallemand Health Solutions
mluneau@lallemand.com